NASDAQ:ESLA Estrella Immunopharma (ESLA) Stock Price, News & Analysis $0.64 0.00 (-0.36%) Closing price 09/9/2026 04:00 PM EasternExtended Trading$0.64 +0.00 (+0.16%) As of 04:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Estrella Immunopharma Stock (NASDAQ:ESLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Estrella Immunopharma alerts:Sign Up Key Stats Today's Range$0.61▼$0.6950-Day Range$0.64▼$1.0252-Week Range$0.59▼$3.15Volume28,575 shsAverage Volume29,209 shsMarket Capitalization$27.75 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingHold Company Overview Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California. Read More Estrella Immunopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreESLA MarketRank™: Estrella Immunopharma scored higher than 31% of companies evaluated by MarketBeat, and ranked 724th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingEstrella Immunopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialEstrella Immunopharma has a consensus price target of $8.00, representing about 1,153.9% upside from its current price of $0.64.Amount of Analyst CoverageEstrella Immunopharma has only been the subject of 1 research reports in the past 90 days.Read more about Estrella Immunopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Estrella Immunopharma are expected to decrease in the coming year, from ($0.25) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Estrella Immunopharma is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Estrella Immunopharma is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.15% of the float of Estrella Immunopharma has been sold short.Short Interest Ratio / Days to CoverEstrella Immunopharma has a short interest ratio ("days to cover") of 2.62, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Estrella Immunopharma has recently increased by 27.79%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEstrella Immunopharma does not currently pay a dividend.Dividend GrowthEstrella Immunopharma does not have a long track record of dividend growth. News and Social Media1.6 / 5News SentimentN/A News SentimentEstrella Immunopharma has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Estrella Immunopharma this week, compared to 1 article on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Estrella Immunopharma insiders have not sold or bought any company stock.Percentage Held by Insiders5.80% of the stock of Estrella Immunopharma is held by insiders.Percentage Held by Institutions0.35% of the stock of Estrella Immunopharma is held by institutions.Read more about Estrella Immunopharma's insider trading history. Receive ESLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Estrella Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ESLA Stock News HeadlinesWhat is Zacks Research's Estimate for ESLA FY2026 Earnings?September 4, 2026 | americanbankingnews.comESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 TrialAugust 26, 2026 | finance.yahoo.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | Porter & Company (Ad)Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaAugust 11, 2026 | finance.yahoo.comEstrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaJuly 29, 2026 | finance.yahoo.comEstrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s LymphomaJuly 24, 2026 | finance.yahoo.comEstrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin's LymphomaJuly 24, 2026 | businesswire.comESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma?July 14, 2026 | finance.yahoo.comSee More Headlines ESLA Stock Analysis - Frequently Asked Questions How have ESLA shares performed this year? Estrella Immunopharma's stock was trading at $1.56 at the start of the year. Since then, ESLA stock has decreased by 59.1% and is now trading at $0.6380. How were Estrella Immunopharma's earnings last quarter? Estrella Immunopharma, Inc. (NASDAQ:ESLA) issued its quarterly earnings data on Thursday, August, 13th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.04. Who are Estrella Immunopharma's major shareholders? Estrella Immunopharma's top institutional shareholders include BlackRock Inc. (0.12%). View institutional ownership trends. How do I buy shares of Estrella Immunopharma? Shares of ESLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Estrella Immunopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Estrella Immunopharma investors own include NuCana (NCNA), Cardio Diagnostics (CDIO), Caribou Biosciences (CRBU), GRI Bio (GRI), Intrusion (INTZ), Children's Place (PLCE). Company Calendar Last Earnings8/13/2026Today9/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ESLA's financial health is in the Yellow zone, according to TradeSmith. ESLA has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ESLA CIK1844417 Webwww.estrellabio.com Phone510-318-9098FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Estrella Immunopharma$8.00 High Price Target$8.00 Low Price Target$8.00 Potential Upside/Downside+1,153.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.06 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-328.72% Debt Debt-to-Equity RatioN/A Current Ratio0.20 Quick Ratio0.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / Book-2.36Miscellaneous Outstanding Shares43,500,000Free Float40,975,000Market Cap$27.75 million OptionableNot Optionable Beta0.88 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ESLA) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our PartnersThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
